

Regioselective synthesis of pyrimido[1,2-*a*][1,3,5]triazin-6-ones via reaction of 1-(6-oxo-1,6-dihydropyrimidin-2-yl)guanidines with triethylorthoacetate: observation of an unexpected rearrangement†Nikhil Sachdeva,^a Anton V. Dolzhenko^b and Wai Keung Chui*^a

Received 26th January 2012, Accepted 3rd April 2012

DOI: 10.1039/c2ob25195g

A novel thermal rearrangement, involving pyrimidine ring opening and subsequent ring closure leading to recyclization of the system, was identified in the reaction of (6-oxo-1,6-dihydropyrimidin-2-yl)guanidines **3** (where NR¹R² = NH₂, NH alkyl, NH aralkyl, NHCH₂Ph(R)) with triethyl orthoacetate, affording 4-substituted-2-methyl-6*H*-pyrimido[1,2-*a*][1,3,5]triazin-6-ones **6** and their ring opened products. However, no such rearrangement was observed with (6-oxo-1,6-dihydropyrimidin-2-yl)guanidines **3** bearing a tertiary amino or anilino substituent (*i.e.* where NR¹R² = N(CH₃)₂, indoline, morpholino, NHAr). As expected, 2-substituted-4-methyl-6*H*-pyrimido[1,2-*a*][1,3,5]triazin-6-ones **4** were obtained as the final products. Experimental structural determination and theoretical studies were carried out to get an understanding of the observed thermal rearrangement. In addition, an attempt to obtain similar pyrimido[1,2-*a*][1,3,5]triazin-6-ones using *N,N*-dimethylacetamide dimethyl acetal (DMA–DMA) as one carbon inserting synthon had furnished triazine ring annulated product **14** bearing *N,N*-dimethyl enamino substituent at position 4 as a result of further reaction with a second molecule of DMA–DMA.

Introduction

1,3,5-Triazine nucleus is a prominent structural core present in numerous biologically active compounds. Hexamethylmelamine, irsogladine and 5-aza-2'-deoxycytidine, which are structurally based on the 1,3,5-triazine scaffold, have been found to exhibit anti-cancer and antiangiogenic properties.¹ Various 1,3,5-triazine derivatives fused to quinazoline,² benzimidazole,³ pyrazole^{4,5} and 1,2,4-triazine⁶ have been reported to show anti-cancer properties. Moreover, numerous derivatives of pyrimidine fused systems such as pyrido[2,3-*d*]pyrimidine (PD-0332991)⁷ and pyrimido[1,2-*a*]pyrimidine (**4**)⁸ have also demonstrated promising anticancer properties as well. Due to the close structural similarity with the above pyrimido fused bicyclic scaffolds and reports on antiproliferative activity from 1,3,5-triazino fused heterocycles, the derivatives of pyrimido[1,2-*a*][1,3,5]triazine scaffold were anticipated to possess anticancer property (Fig. 1). To date, heterocyclic compounds possessing a pyrimido[1,2-*a*-

[1,3,5]triazine moiety have been reported to exhibit antimicrobial,⁹ potent fungicidal and average serotonergic (5-HT_{1A} and 5-HT_{1B} receptor) activities¹⁰ as well as GSK-3β inhibitory activity with potential for the treatment of neurodegenerative diseases.¹¹

In the literature, synthetic access to pyrimido[1,2-*a*][1,3,5]triazine analogues (in which one of the four nitrogen atoms is located at the junction of the two cycles) is rather limited and most of the synthetic approaches described cannot provide the flexibility of different substitution at various positions around the fused rings. The synthesis of pyrimido[1,2-*a*][1,3,5]triazine system¹² can be categorized into two approaches: (1) annulation of pyrimidine onto a 1,3,5-triazine scaffold;¹³ (2) annulation of the 1,3,5-triazine ring onto a pyrimidine scaffold.¹⁴ The latter approach has been largely adopted for the preparation of pyrimido[1,2-*a*][1,3,5]triazines and most authors largely focussed on the formation of dioxo/dithio/oxothiooxo derivatives of the scaffold.^{14*g-p*} Therefore, there is a need to find more practical approaches for the synthesis of these pyrimido[1,2-*a*][1,3,5]triazines.

Since orthoesters are versatile one-carbon building blocks in ring annulation reactions, it was expected that unsymmetrically substituted pyrimidin-2-yl guanidine **3** (acting as a penta atomic synthon) would react with this one-carbon building block to yield, theoretically, either one of the regioisomeric pyrimido[1,2-*a*][1,3,5]triazin-6-ones **4** or **5** or both as product/s. However, the possibility of structure **5** was excluded, as no cross-peaks were found between the R³ group protons of pyrimidine ring and

^aDepartment of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore. E-mail: phacwk@nus.edu.sg, nicks.sachdeva81@gmail.com; Fax: +65 6779 1554; Tel: +65 6516 2933

^bSchool of Pharmacy, Curtin Health Innovation Research Institute, Curtin University of Technology, GPO Box 1987, Perth, Western Australia 6845, Australia

†Electronic supplementary information (ESI) available. CCDC 791289, 788427 and 838638. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c2ob25195g





Fig. 1 Structurally similar nitrogen containing heterocyclic scaffolds.



Scheme 1 Reagents and Conditions: (i) ethyl 3-oxobutanoate/ethyl 4,4,4-trifluoro-3-oxobutanoate, aq. NaOH, r.t., 12 h (77%); (ii) procedure 1 HNR¹R², HCl, MW, 160 °C, 15 min or procedure 2 NR¹R², TMSCl, CH₃CN, 12 min., 160 °C followed by iPrOH, 125 °C, 30 sec. (62%–79%); (iii) HNR¹R²-HCl, C₄H₉OH, reflux, 6 h (40%); (iv) CH₃C(OEt)₃, AcOH, reflux, 3–9 h.

methyl group protons of triazine ring in 2D NOESY experiment (Scheme 1). Moreover, according to DFT calculations in gas phase, the structure **5** was found to be highly unfavourable energetically (*vide infra*). In addition, a regioisomeric product similar to **4** was observed exclusively when other one-carbon inserting synthon like aldehyde was used with similar substrate.¹⁵ However, to our surprise, products **4** (Table 1) were found readily rearranged *in situ* to thermodynamically more favourable products of type **6** and the corresponding ring-opened products **6'** (Scheme 3), depending upon the NR¹R² group present in the starting material guanidine (Table 2). Herein, the details of this unexpected thermal rearrangement are presented.

Results and discussion

The starting material *N*-(4-substituted-6-oxo-1,6-dihydropyrimidin-2-yl)guanidines, **3**, were prepared either by method A or B

(Scheme 1). In method A, **3** was synthesized *via* microwave (MW) assisted nucleophilic addition of amines onto (4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)cyanamide **1** using either concentrated hydrochloric acid or trimethyl silyl chloride (TMSCl) catalyzed conditions; whereas in method B, cyclocondensation of β-keto ester with substituted biguanides **2** yielded **3** as reported by Curd *et al.*¹⁶ (Scheme 1). Method A was found to be more versatile and robust for molecular library generation. In the presence of protic acid (method A procedure 1) or TMSCl (method A procedure 2) catalyzed conditions, the reaction times were shorter, workup was easy obviating the need of column chromatography and appreciable yields of **3** (56–93%) were obtained with a variety of primary and secondary amines with alkyl, aryl and aralkyl substituents. In the latter case (*i.e.* method A procedure 2), TMSCl not only acted as a source of anhydrous HCl, but it also activated cyanamide **1** as shown in Scheme 2.

Table 1 Structures and yields of intermediates and isolated pyrimido[1,2-*a*][1,3,5]triazin-6-one products


























3	Isolated product	Isolated yield (%)
 <p>3a</p>	 <p>6a</p>	70
 <p>3b</p>	 <p>6b</p>	58
 <p>3c</p>	 <p>6c</p>	60
 <p>3d</p>	 <p>4d</p>	52
 <p>3e</p>	 <p>4e</p>	73
 <p>3f</p>	 <p>4f</p>	33

Table 1 (Contd.)

3	Isolated product	Isolated yield (%)
 <p>3g</p>	 <p>6g</p>	38
 <p>3h</p>	 <p>6h</p>	53
 <p>3i</p>	 <p>4i</p>	59
 <p>3j</p>	 <p>4j</p>	78
 <p>3k</p>	 <p>4k</p>	69
 <p>3l</p>	 <p>4l</p>	71

The structures of the products were deduced from their mass spectra, NMR data and elemental analyses. The reactions were carefully monitored using TLC and the reactions were stopped

immediately when no trace of the starting material was observed. The reaction proceeded only on heating at 100 °C. The reaction between these guanidines (**3**) and triethyl orthoacetate (in



Scheme 2 Synthesis of 1,6-dihydropyrimidinyl guanidines **3** under TMSCl catalyzed conditions.

Table 2 Relative energies according to *ab-initio* calculations

	Relative energies, kcal mol ⁻¹		
	4	5	6
a R ¹ = R ² = H	4.14	21.81	0.00
i R ¹ = R ² = CH ₃	0.00	17.65	8.72

presence of glacial acetic acid) yielded product **4** predominantly when the guanidine **3** contained a tertiary amino group (**3i–k**) (NR¹R² = N(CH₃)₂, –N(CH₂CH₂)₂O, indolino). Similarly when an aryl secondary amino group was included as in **3d**, **3e**, **3f** and **3l** (NR¹R² = NHPPh, NHPPh(3-Br), NHPPh(3-Cl), NHPPh(4-OMe)), the predominant compound was **4**. Product **4** was characterized by the diagnostic methyl peak of the triazine ring at δ 2.85–2.91 in ¹H NMR and 26.2–27.8 in ¹³C NMR as well as X-ray crystallography of **4i** (Fig. 2; please refer to ESI† for structural details). However, upfield shift to δ 2.18–2.29 in ¹H NMR and 25.2–25.6 in ¹³C NMR were observed, surprisingly, in isolated products when unsubstituted (**3a**), alkylsubstituted (**3b**) or aralkyl guanidines (**3g**, **3h**) were used as a substrate under similar conditions. Therefore, the respective product obtained from reactants **3a**, **3b**, **3c**, **3g** and **3h** was expected to have a structure different from **4** even though the mass spectra showed expected values corresponding to structure **4**. Hence, to confirm this aspect, X-ray crystallographic study of the product obtained from **3a** was performed.

The fact that there were clearly differentiated chemical shifts at δ 10.18 and 9.26 for the product obtained by the reaction of triethyl orthoacetate with **3a** in the ¹H NMR spectrum supported the existence of hydrogen bonding between the peri-carbonyl and the proximate exocyclic N–H which is not possible in structure **4**. Moreover, similar lowfield shifts of NH proton in ¹H NMR from 10.18–13.20 ppm were observed in **6b–c** and **6g–h**. X-ray crystallographic study¹⁷ of this product (Fig. 3) revealed that the product **4a** (not isolated) underwent a smooth rearrangement to an isomeric product **6a** *in situ* as suspected from NMR studies. So, structure **6** was assigned to the rearranged product with upfield shift, in the cases of **3a**, **3b**, **3c**, **3g** and **3h**. Moreover, NMR studies were found to be consistent with the X-ray crystallographic data of **6a** (Fig. 3) where hydrogens attached to N5 have unequal bond lengths and the amino group was found to be locked in the plane of pyrimido[1,2-*a*][1,3,5]triazine nucleus due to the π -electron delocalization with the heterocycle.

The proposed mechanism for the formation of rearranged product **6** is depicted in Scheme 3. The reaction starts with the exchange of alkoxy groups of the orthoester (in excess) under acid catalysis, which then reacted with the guanidine **3** (nucleophile) to give iminium ion intermediate **7**. Subsequent loss of EtOH gave **4**. Thermal rearrangement is then assumed to




Fig. 2 X-ray crystal structure of 2-(dimethylamino)-4,8-dimethyl-6H-pyrimido[1,2-*a*][1,3,5]triazin-6-one **4i** (displacement ellipsoids are drawn at 50% probability level) CCDC 791289.






Fig. 3 X-ray crystal structure of 4-amino-2,8-dimethyl-6H-pyrimido[1,2-*a*][1,3,5]triazin-6-one **6a** CCDC 788427.



Scheme 3 Proposed mechanism for the formation of compound **6**.

proceed at around 100 °C for substrates **3a**, **3b**, **3c**, **3f** and **3g** (*i.e.* when either R¹ or R² = H) according to Scheme 3. The




Scheme 4 Alternate plausible mechanism for the rearrangement in pyrimido[1,2-*a*][1,3,5]triazin-6-ones *via* pyrimidine ring opening leading to regioisomeric product **12** instead of proposed **10**.

mechanism may have involved: (a) acid catalyzed ethanolytic ring opening of pyrimidine at amide linkage with the formation of ring open triazine carbenone **6'** (acrylic acids were isolated); (b) intramolecular nucleophilic attack by N-1 nitrogen of 1,3,5-triazine on the carbonyl group and subsequent ring closure that gave final product **6**. It is worth mentioning that the thermally assisted rearrangement of 4-amino-8-methylpyrimido[1,2-*a*][1,3,5]triazin-6-one **8** to 4-amino-6-methylpyrimido[1,2-*a*][1,3,5]triazin-6-one **10** was reported^{14b} to have resulted from 1,3,5-triazine ring opening *via* carbodiimide intermediate **9** (Scheme 4). However, the rearrangement involving pyrimidine ring opening similar to the one proposed in Scheme 3 (depicted using hashed arrows in Scheme 4) leading to product **12** *via* ketene intermediate **11** could not be avoided. Moreover, careful analysis of the provided ¹H NMR spectral data seems to corroborate structure **12** (2-amino-8-methylpyrimido[1,2-*a*][1,3,5]triazin-6-one) as ~1.2 ppm downfield shift of the methine proton (in blue) signal on the triazine ring after the rearrangement can only be accounted to the deshielding effect of the neighboring carbonyl group in **12**.

Intramolecular hydrogen bonding between the 4-amino hydrogen and carbonyl oxygen (Fig. 3) as well as involvement of amino group (directly attached to the ring) in π -electron delocalization with the pyrimido[1,2-*a*][1,3,5]triazin-6-one nucleus provides additional stability to the rearranged product **6** which might provide the driving force for such a rearrangement. Therefore, an attempt was made to assess the relative stability of the two possible cyclocondensation products-**4** and **6** in gas phase for substitutions **a** ($R^1 = R^2 = H$) and **i** ($R^1 = R^2 = Me$) using Gaussian 03 software package.¹⁸ Regioisomer **5** was also included in the study as the similar cyclization of benzimidazol-2-yl guanidines (unsymmetrically substituted in the phenylene fragment) with one carbon inserting reagents did not proceed regioselectively in one of our previous works.³ The results of these calculations are presented in Table 2. Rearranged product **6a** was found to be energetically more favourable than **4a** whereas **4i** was found to be more favourable over **6i** (Table 2). This was found to be in agreement with the experimental observation. Theoretical calculations at B3LYP/6-311G 2d,2p//B3LYP/6-311G d,p explained the formation of exclusively one regioisomeric product as both **5a** and **5i** were highly energetically unfavourable (might be due to steric factors).

In an attempt to obtain similar pyrimido[1,2-*a*][1,3,5]triazin-6-ones, the reaction of **3i** with another one carbon electrophilic



Scheme 5





Fig. 4 X-ray crystal structure of (*E*)-2-(dimethylamino)-4-(2-(dimethylamino)prop-1-enyl)-8-methyl-6*H*-pyrimido[1,2-*a*][1,3,5]triazin-6-one **14** (displacement ellipsoids are drawn at 50% probability level), CCDC 838638.

synthon-DMA-DMA **13** (*N,N*-dimethylacetamide dimethyl acetal) yielded a product having m/z 288.3 (Scheme 5). The product formation started after 1 hour and completed in 2.5–3 hours. The ¹H NMR and ¹³C spectra of the compound had two sets of NMe₂ signals at 3.10 and 3.15 as well as 37.1 and 37.3 ppm respectively. Based on the above observations, results of DEPT experiment, as well as the 2D NOESY crosspeaks, it was suggested that a second molecule of DMA–DMA could have contributed to the =C(CH₃)–NMe₂ fragment, although the stereochemistry around the double bond in the enamine substituent at position 4 could be *E* or *Z*. The structure **14**, a new heterocyclic pyrimido[1,2-*a*][1,3,5]triazin-6-one, was assigned based on the crystal structure (Fig. 4). Analogous product was obtained with **3j** also.

A reaction mechanism for the formation of the product is proposed in Scheme 6. The mechanism of formation of 1,3,5-triazine **14** can be rationalized through the reaction with an iminium ion, MeC(OMe) = ⁺NMe₂, derived from **13** to form the required enamine **15**; this is followed by cyclisation and tautomerization with the loss of HNMe₂ to give **4i** (not isolated in this case) and subsequent reaction with the electrophile from the second molecule of DMA–DMA leading to the isolated product **14**.

The comparison of bond lengths obtained from X-ray crystal structures of three pyrimido[1,2-*a*][1,3,5]triazin-6-ones **6a**, **4i** and **14** revealed interesting findings (Table III, ESI[†]). The C4–N3 bond length (C5–N4 according to crystallographic numbering) in triazine ring of **4i** was found to be unusually short (1.289 Å) suggesting higher order of double bond character whereas C4–N5 bond length (C6–N1 according to



Scheme 6 Mechanistic rationale for the formation of **14**.

crystallographic numbering) of **14** was unusually large suggesting more sp^3 character of bridge head nitrogen. The pyrimidine and 1,3,5-triazine rings were found to be coplanar for both **6a** and **4i** in the crystal structures as well as in their optimized geometries obtained from DFT calculations (*vide infra*). However, C=O of pyrimidine ring bent downwards while the position of 4 enamine side chain of triazine ring is twisted upwards (torsional angle C1–N1–C6–N3 = 20.6°) increasing O...C10 bond distance in **14** to 2.762 Å compared to O...C8 bond distance which is 2.64 Å. Stereochemistry of the enamine fragment at position 4 was found to be *E*.

Next, the antiproliferative activity of the synthesized compounds was assessed using MTT assay.¹⁹ In particular, lung A549 and MDA-MB-231 breast cancer cell lines were used. No appreciable antiproliferative activity was obtained for all the synthesized compounds except for 2-(3-chlorophenylamino)-4,8-dimethyl-6*H*-pyrimido[1,2-*a*][1,3,5]-triazin-6-one (**4e**) which demonstrated IC_{50} value of $37.5 \pm 2.8 \mu\text{M}$ and $51.2 \pm 3.5 \mu\text{M}$ for A549 and MDA-MB231 cell line respectively.

Conclusion

In summary, the reactions of *N*-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidines with triethyl orthoacetate were investigated. 2-amino-4-methylpyrimido[1,2-*a*][1,3,5]triazin-6-ones **4** and the products of unexpected rearrangement, namely 4-amino-2-methylpyrimido[1,2-*a*][1,3,5]triazin-6-ones **6**, were obtained depending upon the starting guanidine **3**. The rearrangement involved opening of the pyrimidine ring as was shown by isolation of acrylic acid intermediates. The requirements for the rearrangement were discussed on the basis of results obtained from experimental and theoretical studies. This approach opened the opportunities to insert different substituents at position 2 and position 4 of triazine ring, depending upon the starting guanidine. The attempt to obtain similar pyrimido[1,2-*a*][1,3,5]triazin-6-ones using DMA–DMA was unsuccessful, as unexpected cyclocondensation product **14** formed as a result of overreaction. Further work is in progress to explore the propensity of the reagent to form C–C bond formation.

Experimental

General

Melting points (uncorrected) were determined on a Gallenkamp melting point apparatus. NMR spectra were recorded on a Bruker DPX-300 spectrometer using $\text{Me}_2\text{SO}-d_6$ as a solvent and TMS as an internal reference. IR spectra were performed on a Perkin Elmer Spectrum 100 FT-IR spectrophotometer in potassium bromide pellets. Mass spectra were obtained on a Shimadzu LCMS-IT-TOF system using electron spray ionization (ESI) mode. The course of the reactions was monitored by TLC on Silica gel 60 F₂₅₄ plates (Merck, Germany). HPLC analysis was performed on an Agilent Eclipse XDB-C18 (4.6 × 250 mm, 5 μm) column at 30 °C, with a flow rate of 1 mL min⁻¹ 5–90% Gradients of MeOH/MeCN (solvent A) and H₂O (solvent B) were used as mobile phases. Microwave reactions were conducted using a commercially available monomode microwave unit (CEM Discover). Elemental analyses were performed on the Perkin Elmer 2400 Elemental Analyzer Series II.

Crystal structure determinations. The single-crystal X-ray diffraction study was carried out on a Bruker APEX diffractometer attached to a CCD detector and graphite-monochromated $\text{MoK}\alpha$ radiation (λ , 0.71073 Å) using a sealed tube. Absorption corrections were made with the program SADABS²⁰ and the crystallographic package SHELXTL²¹ was used for all calculations.

General method for the preparation of 3a–j

Method A procedure 1. Into a 5 mL microwave vessel was added *N*-(4-substituted-6-oxo-1,6-dihydropyrimidin-2-yl)cyanamide (2 mmol) followed by amine hydrochloride (2.12 mmol) and isopropanol/ACN (1.0 ml). The vial was sealed and the mixture was irradiated at 160–170 °C for 15 min and allowed to cool. The white solid obtained was filtered, washed with solution of sodium hydrogen carbonate and cold water and dried.

Procedure 2. Into a 5 mL microwave vessel was added *N*-(4-substituted-6-oxo-1,6-dihydropyrimidin-2-yl)cyanamide (2 mmol), amine (2.1 mmol) followed by the slow addition of a 2 N solution of TMSCl (1.04 mL, 2.1 mmol, 1.1 equiv) in CH_3CN under cold conditions. After the vial was capped, reaction mixture was irradiated for 12 min at 160 °C. After the mixture was cooled to approximately 60 °C, *i*PrOH (0.55 mL, 6 mmol, 3.0 equiv) was added. The mixture was stirred for 10 s and then irradiated a second time at 125 °C for 30 s. Upon cooling, the hydrochloride salts of guanidines **3** precipitated, and it was collected, washed with cold CH_3CN and then with solution of sodium hydrogen carbonate and cold water and finally dried to obtain slightly better yields of pyrimidinyl guanidines.

Method B. Biguanides were synthesized according to Uohama and Sakai²² and subsequent pyrimidine ring annulation was done using method described by Curd *et al.*¹⁶

Experimental data for some representative compounds:

***N*-(4-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3a).** Yield: 93%; Method B; mp >300 °C; lit²³ mp 304–305 °C; ¹H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.08 (3H, s, Me), 5.58 (1H, s,

H-5), 8.03 (4H, br. s, guanidino NHs), 11.52 (1H, br. s, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): δ 23.2 (Me), 103.0 (CH), 158.5, 159.8, 163.0 (br. s), 166.9 (br. s).

1-(6-Oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)guanidine (3b). Yield: 37%; Method B (using NaOMe instead of aq NaOH in second step); mp 273 °C (decomposed); lit²⁴ mp 273 °C; LC-MS (APCI) m/z = 229.1 (MH^+); ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 6.24 (1H, s, CH), 7.87 (2H, d, J = 7.9 Hz, H-2' and H-6'), 7.38–7.49 (3H, m, H-3', H-4' and H-5'), 8.27 (4H, br. s, $\text{NHC}(=\text{NH})\text{NH}_2$), 11.53 (1H, s, NH).

***N*-Methyl-*N'*-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3c).** Yield 62%; Method A (procedure 1/2); mp 272–273 °C; TLC (silica gel, $\text{MeOH}/\text{CH}_2\text{Cl}_2$, 1 : 6): R_f 0.38. ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.03 (3H, s, CH_3), 2.75 (3H, d, 3J = 4.5 Hz, NCH_3), 5.49 (1H, s, H-5), 7.96–9.20 (3H, br. s, $\text{NH}-\text{C}(=\text{NH})\text{NH}$), 10.86 (1H, br. s, NH).

1-(4-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-3-phenylguanidine (3d). Yield 90%; Method A (procedure 1/2) or Method B; mp 248–249 °C; lit²⁵ mp 244–246 °C; ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.09 (3H, s, Me), 5.60 (1H, s, CH), 7.00 (1H, t, J = 7.2 Hz, H-4'), 7.26 (2H, t, J = 7.5 Hz, H-3' and H-5'), 7.66 (2H, d, J = 7.5 Hz, H-2' and H-6'), 8.12 (2H, br. s, $\text{NH}-\text{C}(=\text{NH})\text{N}$), 9.04 (1H, s, NH), 11.18 (1H, s, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): 23.5 (Me), 103.7 (C-6), 120.3, 122.3, 128.6, 138.9, 155.9, 158.3, 163.0, 163.7.

1-(3-Chlorophenyl)-3-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3e). Yield 90%; Method A (procedure 1/2) or Method B; mp 235–236 °C; lit²⁶ mp 239 °C; ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.10 (s, 3H, CH_3), 5.62 (s, 1H, CH), 7.02 (dd, 1H, J = 7.9 Hz, 1.2 Hz, H-4'), 7.26 (t, 1H, J = 8.1 Hz, H-5'), 7.63 (d, 1H, J = 7.9 Hz, H-6'), 7.75 (s, 1H, H-2'), 8.24 (br. s, 2H), 9.10 (s, 1H, NH), 11.43 (s, 1H, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): 26.7 (CH_3), 107.4 (C-5), 121.8, 122.5, 125.2, 133.4, 136.3, 144.0 (C-1'), 158.9, 161.5, 166.2, 167.0.

1-(4-Methoxyphenyl)-3-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3f). Yield 76%; Method A (procedure 1/2) or Method B; mp 256–258 °C lit²⁷ mp 259–260 °C; ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.01 (3H, s, Me), 3.72 (3H, s, OMe), 4.35 (2H, d, J = 4.9 Hz, CH_2), 5.46 (1H, s, CH), 6.89 (2H, d, J = 8.3 Hz, H-3' and H-5'), 7.28 (2H, d, J = 8.7 Hz, H-2' and H-6'), 7.82 (2H, br. s, $\text{NH}-\text{C}(=\text{NH})\text{N}$), 10.67 (1H, s, NH).

1-(4-Chlorobenzyl)-3-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3g). Yield 68%; Method B; mp 227–228 °C; ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.04 (3H, s, Me), 5.22 (2H, s, CH_2), 5.60 (1H, s, H-5), 7.14 (2H, br. s, $\text{NH}-\text{C}(=\text{NH})\text{N}$), 7.33 (2H, d, J = 8.7 Hz, H-3' and H-5'), 7.47 (2H, d, J = 8.7 Hz, H-2' and H-6'), 10.71 (1H, br. s, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): δ 23.4 (Me), 42.7 (CH_2), 101.3 (C-5), 127.8 (C3' and C-5'), 130.0 (C-2' and C-4'), 131.1 (C-1'), 137.7 (C-4'), 157.5 (C-2), 159.7 (C-4), 161.0, 162.6.

***N,N*-Dimethyl-*N'*-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3i).** Yield 59%; Method A (procedure 1/2) or Method B; mp 227–228 °C; TLC (silica gel, $\text{MeOH}/\text{CH}_2\text{Cl}_2$, 1 : 6): R_f 0.57. ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.03 (3H, s, CH_3), 2.97 (6H, s, $\text{N}(\text{CH}_3)_2$), 5.45 (1H, s, H-5), 8.46 (2H, br. s,

$\text{NH}-\text{C}(=\text{NH})\text{N}$), 10.58 (1H, br. s, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): δ 23.6 (CH_3), 36.4 ($\text{N}(\text{CH}_3)_2$), 102.2 (C-5), 157.9 (C-2), 158.3 (C-4), 162.9 (C=NH), 163.7 (C=O).

***N*-(4-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)morpholine-4-carboxamide (3j).** Yield 36%; Method A (procedure 1/2) or Method B; mp 271–272 °C (EtOH); lit²⁸ mp 272–273 °C; ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.03 (3H, s, Me), 2.75 (3H, d, 3J = 4.5 Hz, N Me), 5.49 (1H, s, H-5), 7.96–9.20 (3H, br. s, $\text{NH}-\text{C}(=\text{NH})\text{NH}$), 10.86 (1H, br. s, NH).

***N*-(4-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)indoline-1-carboxamide (3k).** Yield 61%; Method A (procedure 1/2); mp 268–269 °C; ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.10 (3H, s, CH_3), 3.15 (2H, t, 3J = 8.5 Hz, CH_2), 3.97 (2H, t, 3J = 8.5 Hz, CH_2), 6.93 (1H, t, 3J = 7.2 Hz), 7.09 (1H, t, 3J = 7.7 Hz), 7.17 (1H, d, 3J = 7.2 Hz), 8.64 (1H, d, 3J = 8.3 Hz), 11.24 (1H, s, NH). ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): δ 23.5 (CH_3), 26.4 (3'- CH_2), 47.3 (2'- CH_2), 103.5 (C-5), 118.1, 122.1, 124.1, 126.9, 131.6, 142.4, 157.9 (C-2), 155.3 (C-4), 162.7 (C=NH), 163.7 (C=O).

1-(3-Bromophenyl)-3-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-2-yl)guanidine (3l). Yield 70%; mp 161–162 °C (EtOH); ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 6.18 (1H, s, H-7), 7.12–7.28 (2H, m, H_{Ar}), 7.74–7.89 (2H, m, H_{Ar}), 8.32 (1H, br. s, NH), 10.19 (1H, br. s, NH), 12.05 (1H, br. s, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): δ 103.4 (q, $^3J_{\text{C-F}}$ = 3.1 Hz, C-7), 119.1, 120.9 (q, $^1J_{\text{C-F}}$ = 274.4 Hz, CF_3), 121.4, 121.9, 122.8, 125.0, 130.4, 140.8, 150.9 (q, $^2J_{\text{C-F}}$ = 33.3 Hz, C-8), 156.2, 159.5, 163.4.

***N*-(4-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)cyanamide (1).** Yield 61%; mp >300 °C; lit²⁹ mp >300 °C; TLC (silica gel, $\text{MeOH}/\text{CH}_2\text{Cl}_2$, 1 : 6): R_f 0.43. ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 1.93 (3H, s, Me), 5.20 (1H, s, C-5), 10.22 (1H, s, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): δ 23.8 (Me), 98.7 (C-5), 120.9 (CN), 161.6 (C-2), 164.4 (C-4), 165.6 (C=O).

General method for the preparation of 8(2)-substituted 4(8)-methylpyrimido[1,2-*a*][1,3,5]triazin-6(4)-ones 4 or 6:

Guanidines (3a–j), 0.25 ml acetic acid and excess triethyl orthoacetate were refluxed under nitrogen atmosphere for 0.3–9 h. Solvent was evaporated to dryness on rotary evaporator, purified using column chromatography and finally recrystallised using suitable solvent.

4,8-Dimethyl-2-(phenylamino)-6*H*-pyrimido[1,2-*a*][1,3,5]-triazin-6-one (4d). mp 220–221 °C (EtOAc); TLC (silica gel, 9 : 1 EtOAc/hexane): R_f 0.53; LC-MS (ESI) analysis (m/z) calcd 267.1120; found 268.1141(MH^+). Anal. Calcd for $\text{C}_{14}\text{H}_{13}\text{N}_5\text{O}$ (267.1120): found 62.61, 4.95, 26.03; requires C, 62.91; H, 4.90; N, 26.20. ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.18 (3H, s, 8-Me), 2.90 (3H, s, 4-Me), 5.92 (1H, s, H-7), 7.13 (1H, t, 3J = 7.4 Hz, H-5'), 7.38 (2H, t, 3J = 7.7 Hz, H-3' and H-5'), 7.86 (2H, d, 3J = 7.5 Hz, H-2' and H-6'), 10.63 (1H, s, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): δ 23.7 (2-Me), 26.2 (8-Me), 103.6 (C-5), 120.4 (C-2' and C-6'), 123.9 (C-4'), 128.6 (C-3' and C-5'), 138.0 (C-1'), 152.9, 156.8 (C-2), 160.0, 163.8, 166.7; IR

(KBr); ν 3109 br NH, 1685 C=O, 1627, 1535, 1244, 1036, 821, 752.

2-(3-Chlorophenylamino)-4,8-dimethyl-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (4e). mp 239–240 °C (EtOAc); TLC (silica gel, 9 : 1 EtOAc/hexane): R_f 0.60; LC–MS (ESI) analysis (m/z) calcd 301.0730; found 302.0708 (MH^+); Anal. Calcd for $C_{14}H_{12}ClN_5O$ (301.0730): found: C, 55.49; H, 4.05; Cl 11.50; N, 22.98; requires C, 55.73; H, 4.01; Cl, 11.75; N, 23.21. 1H NMR (300 MHz, Me_2SO-d_6): δ 2.19 (1H, s, 8-Me), 2.91 (1H, s, 4-Me), 5.96 (1H, s, H-7), 7.18 (1H, d, $^3J = 8.3$ Hz, H-4'), 7.40 (1H, t, $^3J = 8.1$ Hz, H-5'), 7.76 (1H, d, $^3J = 7.9$ Hz, H-6'), 8.06 (1H, s, H-2'), 10.79 (1H, s, NH); ^{13}C NMR (75 MHz, Me_2SO-d_6): 23.8 (8-Me), 26.2 (4-Me), 104.0 (C-7), 118.7, 119.5, 123.5, 130.3, 133.0, 139.7 (C-1'), 152.7, 156.9, 160.0, 164.3, 166.7; IR (KBr); ν 3273 br NH, 3103 (CH), 3082, 1678 C=O, 1636, 1095, 866, 788, 717.

2-(4-Methoxyphenylamino)-4,8-dimethyl-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (4f). mp 177–178 °C (EtOAc); TLC (silica gel, 9 : 1 hexane/EtOAc): R_f 0.25; LC–MS (ESI) analysis (m/z) calcd 297.1226; found 298.1296 (MH^+); Anal. Calcd for $C_{15}H_{15}N_5O_2$ (297.1226): found: C, 60.47; H, 5.10; N, 23.29; requires: C, 60.60; H, 5.09; N, 23.56. 1H NMR (300 MHz, Me_2SO-d_6): δ 2.16 (3H, s, 8-Me), 2.88 (3H, s, 4-Me), 3.75 (3H, s, OMe), 5.89 (1H, s, H-7), 6.96 (2H, d, $^3J = 8.8$ Hz, H-3' and H-5'), 7.74 (2H, d, $^3J = 8.8$ Hz, H-2' and H-6'), 10.52 (1H, s, NH); ^{13}C NMR (75 MHz, Me_2SO-d_6): 23.7 (4-Me), 26.2 (8-Me), 55.2 (OMe), 103.2 (C-7), 113.8 (C-2' and C-6'), 122.1 (C-3' and C-5'), 130.9 (C-1'), 153.1 (C-4'), 155.8, 156.5, 160.1, 163.5, 166.7; IR (KBr); ν 3109, 2920 (CH), 2850, 1670 C=O, 1627, 1541, 1419, 1236, 1174, 1028, 831, 788.

2-(Dimethylamino)-4,8-dimethyl-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (4i). mp 190–191 °C (EtOAc); TLC (silica gel, CH_2Cl_2): R_f 0.30; LC–MS (ESI) analysis (m/z) calcd 219.112; found 220.1198 (MH^+); Anal. Calcd for $C_{10}H_{13}N_5O$ (219.112): found: C, 54.42; H, 5.87; N, 31.69; requires: C, 54.78; H, 5.98; N, 31.94. 1H NMR (300 MHz, Me_2SO-d_6): δ 2.12 (3H, s, 8-Me), 2.85 (3H, s, 4-Me), 3.14 (3H, s, $N(Me)_2$), 3.25 (3H, s, $N(Me)_2$), 5.78 (1H, s, H-7); ^{13}C NMR (75 MHz, Me_2SO-d_6): δ 23.8 (8-Me), 26.6 (4-Me), 36.3 ($N(Me)_2$), 36.4 ($N(Me)_2$), 101.8 (C-7), 153.1, 158.0, 160.1, 163.5, 167.2 (C=O); IR (KBr); ν 3420 br NH, 3034 (CH), 2978, 1714, 1670 C=O, 1620, 1516, 1317, 1238, 1192, 1078, 1033, 966, 825, 794, 717.

4,8-Dimethyl-2-morpholino-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (4j). mp 191–192 °C; TLC (silica gel, 9 : 1 CH_2Cl_2 /hexane): R_f 0.40; LC–MS (ESI) analysis (m/z) calcd 261.1; found 262.0 (MH^+); Anal. Calcd for $C_{12}H_{15}N_5O_2$ (261.1): found C, 55.22; H, 5.77; N, 26.86; requires: C, 55.16; H, 5.79; N, 26.80. 1H NMR (300 MHz, Me_2SO-d_6): δ 2.13 (3H, s, 8-Me), 2.86 (3H, s, 4-Me), 3.67 (4H, t, $J = 4.5$ Hz, $(CH_2)_2O$), 3.78 (2H, t, $J = 4.3$ Hz, $N(CH_2)$), 3.89 (2H, t, $J = 4.3$ Hz, $N(CH_2)$), 5.81 (1H, s, H-7); ^{13}C NMR (75 MHz, Me_2SO-d_6): δ 25.0 (8-Me), 27.8 (4-Me), 44.8 (CH_2), 45.3 (CH_2), 66.7 (CH_2), 67.1 (CH_2), 103.3 (C-7), 154.4, 158.3, 161.2, 165.5, 168.3 (C=O); IR (KBr); ν 3388 br NH, 3076 (CH), 2950, 1627 C=O, 1543, 1508, 1406, 1352, 1246, 1181, 1028, 966, 834.

2-(Indolin-1-yl)-4,8-dimethyl-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (4k). mp 212–213 °C (EtOAc); TLC (silica gel, 9 : 1 EtOAc/hexane): R_f 0.32; Anal. Calcd for $C_{16}H_{15}N_5O$ (293.1277): found C, 65.27; H, 5.14; N, 23.74; requires: C, 65.52; H, 5.15; N, 23.88. 1H NMR (300 MHz, Me_2SO-d_6): δ 2.18 (3H, s, 8-Me) and 2.21 (3H, s, 8-Me), 2.94 (3H, s, 4-Me) and 3.00 (3H, s, 4-Me), 3.20 (2H, t, $^3J = 8.5$ Hz, 3' CH_2), 4.19 (1H, t, $^3J = 8.3$ Hz, CH_2) and 4.32 (1H, t, $^3J = 8.9$ Hz, CH_2), 5.92 (2H, s, CH), 6.98–7.16 (2H, m, H-4'), 7.21–7.40 (4H, m, H-5' and H-6'), 8.29 (1H, d, $^3J = 8.2$ Hz, H-7'), 8.49 (1H, d, $^3J = 8.1$ Hz, H-7'); ^{13}C NMR (75 MHz, Me_2SO-d_6): δ 23.5 (Me), 26.4 (3' CH_2), 47.3 (2' CH_2), 103.5 (C-5), 118.1, 122.1, 124.1, 126.9, 131.6, 142.4, 157.9 (C-2), 155.3 (C-4), 162.7 (C=NH), 163.7 (C=O). IR (KBr); ν 3446 br NH, 2935 (CH), 2918, 2854, 1707 C=O, 1624, 1576, 1481, 1456, 1249, 1195, 785.1.

2-(3-Bromophenylamino)-4-methyl-8-(trifluoromethyl)-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (4l). Yield: 70%; mp 216–217 °C (EtOH); TLC (silica gel, 9 : 1 EtOAc/hexane): R_f 0.90. 1H NMR (300 MHz, Me_2SO-d_6): δ 2.91 (1H, s, Me), 6.54 (1H, s, H-7), 7.32–7.42 (2H, m, H-4' and H-5'), 7.86 (1H, d, $^3J = 6.8$ Hz, H-6'), 8.10 (1H, s, H-2'), 11.08 (1H, s, NH); ^{13}C NMR (75 MHz, Me_2SO-d_6): δ 26.07 (CH_3), (C-4), 103.3 (q, $^3J_{C-F} = 2.6$ Hz, C-7), 119.5, 120.6 (q, $^1J_{C-F} = 275.4$ Hz, CF_3), 121.5, 122.8, 127.1, 130.8, 139.2, 152.6 (q, $^2J_{C-F} = 34.0$ Hz, C-8), 155.1, 157.2, 160.2, 164.4; IR (KBr); ν 3282 NH, 3081, 2945, 1699 C=O, 1631, 1608, 1587, 1552, 1465, 1375, 1340, 1278, 1192, 1155, 1101, 1083, 925, 875, 788, 707; % purity >95% $t_R = 7.1$ min.

4-Amino-2,8-dimethyl-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (6a). mp 264–265 °C; TLC (silica gel, CH_2Cl_2): R_f 0.55; LC–MS (ESI) analysis (m/z) calcd 191.0807; found 192.0841 (MH^+); Anal. Calcd for $C_8H_9N_5O$ (191.0807): found C, 50.35; H, 4.95; N, 36.03; requires: C, 50.26; H, 4.74; N, 36.63. 1H NMR (300 MHz, Me_2SO-d_6): δ 2.18 (1H, s, 2-Me), 2.24 (1H, s, 8-Me), 6.04 (1H, s, H-7), 9.26 (1H, s, NH), 10.18 (1H, s, NH); ^{13}C NMR (75 MHz, Me_2SO-d_6): 23.8 (8-Me), 25.2 (2-Me), 104.6 (C-7), 152.9, 156.8, 162.7, 167.6, 172.7; IR (KBr); ν 3294 NH, 3116 br, 1695 C=O, 1647, 1575, 1400, 1197, 1170, 1060, 821, 792, 748, 702.

4-Amino-2-methyl-8-phenyl-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (6b). Yield: 58%; mp 258–259 °C (80 : 20 EtOAc/hexane); TLC (silica gel, 9 : 1 EtOAc/hexane): R_f 0.45; % purity >95%; t_R 8.9 min. 1H NMR (300 MHz, Me_2SO-d_6): δ 2.29 (1H, s, 2- CH_3), 6.77 (1H, s, H-7), 7.44–7.61 (3H, m, H-3', H-4', H-5'), 8.12 (2H, d, $^3J = 8.1$ Hz, H-2' and H-6'), 9.32 (1H, s, NH), 10.22 (1H, s, NH); ^{13}C NMR (75 MHz, Me_2SO-d_6): 25.2 (2- CH_3), 101.2 (C-7), 127.1, 128.6, 131.1, 135.6 (C-1'), 153.4, 156.8, 162.3, 163.6, 172.9; IR (KBr); ν 3344 NH, 3213, 1674 C=O, 1624, 1570, 1544, 1448, 1382, 1220, 1174, 908, 778.

2,8-Dimethyl-4-(methylamino)-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (6c). mp 166–167 °C (EtOAc); TLC (silica gel, 9 : 1 EtOAc/hexane): R_f 0.16; LC–MS (ESI) analysis (m/z) calcd 205.0964; found 206.0946 (MH^+); Anal. Calcd for $C_9H_{11}N_5O$ (205.0964): found: C, 52.49; H, 5.69; N, 32.83; requires: C, 52.67; H, 5.40; N, 34.13. 1H NMR (300 MHz, Me_2SO-d_6): δ 2.18 (3H, s, 2-Me), 2.28 (3H, s, 8-Me), 2.98 (3H, d, $J = 4.9$ Hz,

NMe), 6.07 (1H, s, H-7), 10.90 (1H, d, $J = 4.5$ Hz, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): 23.7 (8-Me), 25.6 (2-Me), 28.4 (NMe), 104.8 (C-7), 152.6, 155.5, 163.0, 167.5, 172.3; IR (KBr); ν 3324 NH, 3201, 1690 C=O, 1642, 1574, 1440, 1187, 1165, 1065, 793, 774.

4-(4-Chlorobenzylamino)-2,8-dimethyl-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (6g). mp 133–134 °C; TLC (silica gel, 9 : 1 EtOAc/hexane): R_f 0.8; LC–MS (ESI) analysis (m/z) calcd 315.0887; found 316.0817 (MH^+); Anal. Calcd for $\text{C}_{15}\text{H}_{14}\text{ClN}_5\text{O}$ (315.0887): found C, 56.99; H, 4.51; Cl 11.44; N, 22.05; requires C, 57.06; H, 4.47; Cl, 11.23; N, 22.18. ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.19 (3H, s, 8-Me), 2.25 (3H, s, 2-Me), 4.69 (2H, s, CH_2), 6.08 (1H, s, H-7), 7.39 (2H, d, $^3J = 8.7$ Hz, H-3' and H-5'), 7.43 (2H, d, $^3J = 8.7$ Hz, H-2' and H-6'), 11.43 (1H, br. s, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): 23.8 (2-Me), 25.6 (8-Me), 43.9 (CH_2), 105.0 (C-7), 128.3 (C-3' and C-5'), 129.5 (C-2' and C-6'), 131.8 (C-4'), 136.4 (C-1'), 152.7, 155.2, 163.2, 167.6, 172.3; IR (KBr); ν 3170 br NH, 1689 C=O, 1618, 1411, 1377, 1344, 827, 794, 711.

4-(4-Methoxybenzylamino)-2,8-dimethyl-6H-pyrimido[1,2-*a*]-[1,3,5]triazin-6-one (6h). mp 138–139 °C; TLC (silica gel, 9 : 1 EtOAc/hexane): R_f 0.26; LC–MS (ESI) analysis (m/z) calcd 311.1382; found 312.1409 (MH^+); Anal. Calcd for $\text{C}_{16}\text{H}_{17}\text{N}_5\text{O}_2$ (311.1382): found: C, 61.78; H, 5.42; N, 22.52; requires: C, 61.72; H, 5.50; N, 22.49. ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.19 (3H, s, 2-Me), 2.28 (3H, s, 8-Me), 3.74 (3H, s, OMe), 4.62 (2H, d, $J = 5.7$ Hz, CH_2), 6.07 (1H, s, H-3), 6.91 (1H, d, $^3J = 8.7$ Hz, H-3' and H-5'), 7.34 (1H, d, $^3J = 8.3$ Hz, H-2' and H-6'), 11.36 (1H, t, $J = 5.7$ Hz, NH); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): 23.8 (8-Me), 25.6 (2-Me), 44.1 (CH_2), 55.0 (OMe), 104.9 (C-7), 113.8 (C-2' and C-6'), 128.9 (C-1'), 129.2 (C-3' and C-5'), 152.6 (C-4'), 155.1, 158.6, 163.3, 167.7, 172.4; IR (KBr); ν 3109 br NH, 2950 (CH), 1683 C=O, 1629, 1516, 1458, 1379, 1342, 1172, 1114, 1026, 821, 792.

3-(6-Methyl-4-(phenylamino)-1,3,5-triazin-2(1H)-ylideneamino)but-2-enoic acid (6'd). LC–MS (ESI) analysis (m/z) calcd 285.1226; found 285.1293 (MH^+); TLC (silica gel, 9 : 1 EtOAc/hexane): R_f 0.16; Anal. Calcd for $\text{C}_{14}\text{H}_{15}\text{N}_5\text{O}_2$ (285.1226): found C, 56.18, H 4.89, N 23.58; requires C, 58.94; H, 5.30; N, 24.55. ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.17 (3H, s, 8-Me), 2.25 (3H, s, 4-Me), 5.77 (1H, s, CH), 7.13 (1H, t, $J = 7.3$ Hz, H-4'), 7.33 (2H, t, $^3J = 7.7$ Hz, H-3' and H-5'), 7.84 (2H, d, $^3J = 7.9$ Hz, H-2' and H-6'), 10.94 (1H, s, NHPh), 12.06 (1H, br s, NH), 13.75 (1H, br s, COOH).

3-(4-(4-Methoxyphenylamino)-6-methyl-1,3,5-triazin-2(1H)-ylideneamino)but-2-enoic acid (6'f). LC–MS (ESI) analysis (m/z) calcd 315.1331; found 316.1255 (MH^+); TLC (silica gel, 9 : 1 hexane/EtOAc): R_f 0.11; Anal. Calcd for $\text{C}_{15}\text{H}_{17}\text{N}_5\text{O}_3$ (315.1331): found C, 57.44; H, 5.21; N, 22.45; requires C, 57.13; H, 5.43; N, 22.21. ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.17 (3H, s, 8-Me), 2.24 (3H, s, 4-Me), 3.75 (3H, s, OMe), 5.74 (1H, s, CH), 6.87 (2H, d, $^3J = 8.3$ Hz, H-2' and H-6'), 7.74 (2H, d, $^3J = 9.0$ Hz, H-3' and H-5'), 10.82 (1H, s, NHPh), 11.97 (1H, s, NH), 13.72 (1H, s, COOH).

3-(4-(4-Methoxybenzylamino)-6-methyl-1,3,5-triazin-2(1H)-ylideneamino)but-2-enoic acid (6'h). ^1H NMR (300 MHz,

$\text{Me}_2\text{SO}-d_6$): δ 2.12 (3H, s, 4-Me), 2.17 (3H, s, Me), 3.74 (3H, s, OMe), 4.57 (2H, d, $J = 5.7$ Hz, CH_2), 5.66 (1H, s, H-3), 7.37 (2H, d, $^3J = 8.7$ Hz, H-3' and H-5'), 7.48 (1H, d, $^3J = 8.3$ Hz, H-2' and H-6'), 9.30 (1H, t, $J = 5.7$ Hz, NH), 11.63 (1H, br s, NH), 13.72 (1H, s, COOH).

Western blot analysis

Equal amounts of protein (50 μg) in each lysate sample were separated by 10% sodium dodecyl sulfate (SDS)–polyacrylamide gel. Proteins were then electroblotted on nitrocellulose membranes and the blot was probed with a primary antibody followed by a secondary antibody (rabbit anti-PARP, goat anti- β -actin) conjugated to horseradish peroxidase.

(E)-2-(Dimethylamino)-4-(2-(dimethylamino)prop-1-enyl)-8-methyl-6H-pyrimido[1,2-*a*][1,3,5]triazin-6-one (14). Appropriate guanidine and excess equivalent of DMA–DMA (with/without toluene) were refluxed under nitrogen atmosphere. The reaction was monitored using TLC. The solvent was evaporated to dryness on rotary evaporator, purified using column chromatography and finally recrystallized using suitable solvent.

Yield: 73%; physical appearance: orange; mp 212–213 °C (MeOH/EtOAc); LC–MS (ESI) analysis (m/z) calcd 288.17; found: 289.1 (MH^+); Anal. calc. for $\text{C}_{14}\text{H}_{20}\text{N}_6\text{O}$ (288.17): C, 58.31; H, 6.99; N, 29.15; found: 58.54; H, 7.17; N, 28.89. ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.06 (3H, s, 9-Me), 2.64 (3H, s, 4-Me), 3.05 (6H, s, $\text{N}(\text{Me})_2$), 3.05 (6H, s, $\text{N}(\text{Me})_2$), 3.10 (6H, s, $\text{N}(\text{Me})_2$), 5.63 (1H, s, 8-CH), 6.13 (1H, s, =CH-N); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): 18.2 (4-Me), 23.6 (9-Me), 36.2 ($\text{N}(\text{Me})_2$), 36.4 ($\text{N}(\text{Me})_2$), 90.9 (=CH-N), 101.1 (C-8), 154.7, 157.5, 158.4 (C-5), 157.5, 158.4, 161.3, 164.9, 166.1.

(E)-4-(2-(Dimethylamino)prop-1-enyl)-8-methyl-2-morpholino-6H-pyrimido[1,2-*a*][1,3,5]triazin-6-one (14j). Yield: 69%; physical appearance: yellow; mp 217–218 °C (MeOH/EtOAc); LC–MS (ESI) analysis (m/z) calcd 330.1; found: 331.0 (MH^+); ^1H NMR (300 MHz, $\text{Me}_2\text{SO}-d_6$): δ 2.06 (3H, s, 9-Me), 2.61 (3H, s, 4-Me), 3.11 (6H, s, $\text{N}(\text{Me})_2$), 3.65 (4H, m, $(\text{CH}_2)_2$), 3.72 (4H, m, $(\text{CH}_2)_2$), 5.67 (1H, s, 8-CH), 6.17 (1H, s, =CH-N); ^{13}C NMR (75 MHz, $\text{Me}_2\text{SO}-d_6$): 18.5 (4-Me), 23.5 (9-Me), 43.8 (O $(\text{CH}_2)_2$), 65.8 ($\text{N}(\text{CH}_2)_2$), 91.2 (=CH-N), 101.5 (C-8), 154.8, 157.6, 158.0 (C-5), 161.2, 165.4, 165.9; IR (KBr); ν 3352 br., 1681 C=O, 1616, 1565, 1171, 979.

Acknowledgements

This work is supported by the National Medical Research Council, Singapore (NMRC/NIG/0020/2008) and the National University of Singapore (R-148–050–091–101/133 and R-148–000–069–112). The authors thank Koh Lip Lin, Tan Geok Kheng and Woo Su Fen for the X-ray crystallography study and Ms Tan Beejen for assisting in western blot analysis of compound **4e**.

Notes and references

- (a) K. Arya and A. Dandia, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 3298; (b) D. Moreau, C. Jacquot, P. Tsita, I. Chinou, C. Tomasoni, M. Juge, E. A. Vyza, L. Martignat, A. Pineau and C. Roussakis, *Int. J. Cancer*, 2008, **123**, 2676; (c) N. Galili and A. Raza, *Expert Opin. Pharmacother.*, 2010,

- 11, 1889; (d) M. Ono, N. Kawahara, D. Goto, Y. Wakabayashi, S. Ushira, S. Yoshida, H. Izumi, M. Kuwano and Y. Sato, *Cancer Res.*, 1996, **56**, 1512; (e) S. Nozaki, M. Maeda, H. Truda and G. W. Sledze, *Breast Cancer Res. Treat.*, 2004, **83**, 195.
- 2 A. V. Dolzhenko, M. C. Foo, B. J. Tan, A. V. Dolzhenko, G. N. C. Chiu and W. K. Chui, *Heterocycles*, 2009, **78**, 1761.
- 3 A. V. Dolzhenko and W. K. Chui, *J. Heterocycl. Chem.*, 2006, **43**, 95.
- 4 A. V. Dolzhenko, A. V. Dolzhenko and W. K. Chui, *Heterocycles*, 2008, **75**, 1575.
- 5 Z. Nie, C. Perretta, P. Erickson, S. Margosiak, R. Almassy, J. Lu, A. Averill, K. M. Yager and S. Chu, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 4191.
- 6 (a) A. Ghaib, S. Menager, P. Verite and O. Lafont, *Farmaco*, 2002, **57**, 109; (b) I. T. Kay, *Ger. Offen* DE 2452893, 1975.
- 7 D. W. Fry, P. J. Harvey, P. R. Keller, W. L. Elliott, M. Meade, E. Trachet, M. Albassam, X. Zheng, W. R. Leopold, N. K. Pryer and P. L. Toogood, *Mol. Cancer Ther.*, 2004, **3**, 1427.
- 8 E. Bacque, M. Brollo, A. Clauss, Y. El Ahmad, B. Filoche-Romme, F. Halley, K. A. Karlsson, G. Marciniak, B. Ronan, L. Schio, B. Vivet, F. Viviani and A. Zimmermann, *PCT Int. Appl* WO 001113 A2, 2011, 128pp.
- 9 M. A. Waly and M. I. Abou Dohara, *Pol. J. Chem.*, 2009, **83**, 1601.
- 10 L. Lucry, F. Enoma, F. Estour, H. Oulyadi, S. Menager and O. Lafont, *J. Heterocycl. Chem.*, 2002, **39**, 663.
- 11 A. Lothead, M. Saady and P. Yaiche, *Pat* WO 2138488, 2009; *Chem. Abstr.*, **152**, 119689.
- 12 For recent review on pyrimido[1,2-*a*][1,3,5]triazines, see: A. V. Dolzhenko, *Heterocycles*, 2011, **83**, 1489.
- 13 (a) E. Ziegler and E. Noelken, *Monatsh. Chem.*, 1961, **92**, 1184; (b) K. Hoegerle and H. Brechbuehler, *Ger. Offen* DE 2450119, 1975, 17 pp; (c) Y. A. E. Issac, *Bull. Chem. Soc. Jpn.*, 1999, **72**, 503; (d) Y. Singh and R. H. Prager, *Aust. J. Chem.*, 1992, **45**, 1825.
- 14 (a) R. S. Hosmane and N. J. Leonard, *J. Org. Chem.*, 1981, **46**, 1457; (b) Y. S. Agasimundin, F. T. Oakes and N. J. Leonard, *J. Org. Chem.*, 1985, **50**, 2474; (c) I. T. Kay, *Ger. Offen* 2452893, 1975; *Chem. Abstr.*, 1975, **83**, 97363; (d) M. G. Karmouta, O. Lafont, C. Combet-Farnoux and M. Miocque, *C. R. Acad. Sci., Ser. IIc: Sci. Chim.*, 1977, **285**, 25; (e) M. G. Karmouta, O. Lafont, C. Combet-Farnoux, M. Miocque, M. C. Rigotherier, B. Louchon and P. Gayral, *Eur. J. Med. Chem.-Chim. Ther.*, 1980, **15**(4), 341; (f) L. Lucry, F. Enoma, F. Estour, H. Oulyadi, S. Menager and O. Lafont, *J. Heterocycl. Chem.*, 2002, **39**, 663; (g) A. Kamal and P. B. Sattur, *Synthesis*, 1985, 892; (h) S. Kumar and N. J. Leonard, *J. Org. Chem.*, 1988, **53**, 3959; (i) S. Nagai, T. Ueda, A. Nagatsu, K. Nakaoka, N. Murakami, J. Sakakibara, M. Fujita and Y. Hotta, *J. Heterocycl. Chem.*, 1998, **35**, 329; (j) C. V. Greco and K. J. Gala, *J. Chem. Soc., Perkin Trans. 1*, 1981, 331; (k) M. R. Mahmoud, M. S. Abd-El-Halim, A. E. F. Ebrahim and A. M. Radwan, *Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem.*, 1996, **35B**, 915; (l) R. Richter and H. Ulrich, *Chem. Ber.*, 1970, **103**, 3525; (m) M. S. Amine, *Egypt. J. Chem.*, 1998, **41**, 267; (n) M. Sawada, Y. Furukawa, Y. Takai and T. Hanafusa, *Heterocycles*, 1984, **22**(3), 501; (o) P. Camus, M. F. Lhomme and J. Lhomme, *Tetrahedron Lett.*, 1989, **30**(4), 467; (p) J. Boedecker, P. Koeckritz and K. Courault, *Z. Chem.*, 1979, **19**(2), 59; (q) F. Ishikawa, A. Kosasayama, S. Nakamura and T. Konno, *Chem. Pharm. Bull.*, 1978, **26**, 3658.
- 15 A. V. Dolzhenko, N. Sachdeva, G. K. Tan, L. L. Koh and W. K. Chui, *Acta Crystallogr., Sect. E: Struct. Rep. Online*, 2009, **65**, o684.
- 16 F. H. S. Curd, W. Graham and F. L. Rose, *J. Chem. Soc.*, 1948, 549.
- 17 (a) For compound **6a**: N. Sachdeva, A. V. Dolzhenko, G. K. Tan, L. L. Koh and W. K. Chui, *Acta Crystallogr., Sect. E: Struct. Rep. Online*, 2010, **66**, o2050; (b) For compound **4i** and **10**: Crystallographic data have been deposited with the Cambridge Crystallographic Data Centre (deposition number CCDC 791289 and 838638) as supplementary publication.
- 18 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, J. A. Montgomery, T. Vreven, K. N. Kudin, J. C. Burant, J. M. Millam, S. S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J. E. Knox, H. P. Hratchian, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth, P. Salvador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D. Daniels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. Wong, C. Gonzalez and J. A. Pople, *Gaussian 03 (Revision C.02)*, Gaussian, Inc., Wallingford CT, 2004.
- 19 M. C. Alley, D. A. Scudiero, A. Monks, M. L. Hursey, M. J. Czerwinski, D. L. Fine, B. J. Abbott, J. G. Mayo, R. H. Shoemaker and M. R. Boyd, *Cancer Res.*, 1988, **48**, 589.
- 20 G. M. Sheldrick, SADABS, in *Program for Empirical Absorption Correction for Area Detector Data*, University of Göttingen, Göttingen, Germany, 2000.
- 21 G. M. Sheldrick, *Acta Crystallogr., Sect. A: Fundam. Crystallogr.*, 2008, **A64**, 112.
- 22 J. Sakai and M. Uohama, *JP* 97-232411, 1997.
- 23 K. Tetsuzo, C. Takuo, S. Takeshi and T. Hitoshi, *Chem. Pharm. Bull.*, 1981, **29**(3), 862.
- 24 N. Sachdeva, A. V. Dolzhenko and W. K. Chui, *C. R. Chim.*, 2011, **14**, 580.
- 25 F. H. S. Curd, *J. Chem. Soc.*, 1946, 362.
- 26 F. H. S. Curd, *US Pat* 2422890, 1947.
- 27 F. Mitsuru, Y. Takatoshi, G. Motoo and H. Seigoro, *Chem. Pharm. Bull.*, 1973, **21**(12), 2594.
- 28 B. K. Paul, *Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem.*, 1976, **14B**(11), 887.
- 29 (a) M. R. Ganjali, *Anal. Sci.*, 2004, **20**(10), 1427; (b) P. Franz, *J. Prakt. Chem.*, 1909, **77**, 533; (c) A. Mario, O. Daniel, W. Donald, M. Leslie and J. W. McCall, *J. Med. Chem.*, 1983, **26**, 1258.